The Real Cost of Not Having a 24/7 SOC Is Not the Alert You Miss. It Is the Damage You Discover Too Late.
Many biotech leaders believe they do not need 24/7 security monitoring until they are bigger.
That belief is dangerous.
Not because every biotech company needs an enterprise security operation center with a massive internal team. Most companies under $100M do not have the budget, staffing, or operational volume to justify that. The problem is not size. The problem is exposure.
Biotech companies carry assets that are valuable long before the company becomes large. Research data, intellectual property, trial documentation, lab systems, manufacturing files, regulatory evidence, investor communications, and collaboration platforms all become targets before the company has mature security operations.
That is where the real gap starts.
The question is not whether your IT team is competent. They probably are. The question is whether your current model can detect, interpret, escalate, and respond to suspicious activity at 2:00 a.m. on a Saturday when nobody is actively watching.
For many biotech firms, the answer is no.
And that creates a business risk leadership often underestimates.
The Problem Is Not Lack of Security Tools
Most biotech companies are not completely unprotected. They may have endpoint protection, MFA, firewalls, cloud logging, vulnerability scanning, identity controls, email security, and backup systems.
That looks responsible on paper.
But tools are not the same as security operations.
Security tools produce signals. Someone still has to decide which signals matter. Someone has to separate false positives from early-stage compromise. Someone has to understand whether a suspicious login is harmless travel activity or the beginning of credential abuse. Someone has to know whether an endpoint alert is isolated malware or part of a broader attacker movement.
That work cannot be handled effectively by occasional review.
It requires experienced eyes, defined escalation, and response discipline.
This is where biotech companies get exposed. They buy tools. They assign alert review to internal IT. The team already supports users, vendors, cloud systems, lab applications, access requests, backups, collaboration platforms, and executive demands. Security becomes another responsibility added to an already overloaded function.
The result is not negligence. It is delay.
And in cybersecurity, delay is where cost increases.
After-Hours Is Where Weak Security Models Get Exposed
Attackers do not need your team to be asleep forever. They only need a window.
That window may be overnight. It may be a weekend. It may be a holiday. It may be during a board meeting, trial milestone, audit preparation, fundraising push, or clinical deadline when internal teams are focused elsewhere.
For a biotech company, a missed after-hours alert is not just a technical miss. It can become a research continuity problem.
Imagine a compromised account accessing shared research folders overnight. The login appears unusual, but no one reviews it until morning. By then, files may have been copied, permissions may have been changed, persistence may have been established, and additional accounts may have been tested.
Or imagine ransomware activity beginning on a Friday evening. Endpoint alerts send a signal, but the person responsible for security review is unavailable. By Monday morning, the discussion is no longer about prevention. It is about containment, legal notification, insurance, recovery, executive communication, and operational disruption.
That is the difference between a security alert and a business incident.
The real cost of not having a 24/7 SOC is not that an alert was missed. The real cost is that the company allowed an attacker more time to operate before anyone with the right experience took action.
Biotech Has a Different Risk Profile
A typical business may worry about customer records, payment systems, and operational downtime. Biotech has those risks, but it also has something more fragile: the value of future discoveries.
A small biotech may not have massive revenue yet, but it may hold years of research value. Its intellectual property may represent investor confidence, partnership potential, acquisition value, regulatory progress, and competitive advantage.
That changes the security conversation.
If research data is stolen, altered, encrypted, or exposed, the damage may not show up as a simple IT expense. It may show up as delayed studies, weakened investor trust, uncomfortable due diligence questions, partner hesitation, legal exposure, or a lower valuation narrative.
This is why biotech leadership cannot treat 24/7 security monitoring as a luxury reserved for larger companies.
The question is not, “Are we big enough for a SOC?”
The better question is, “Is our research, operations, and investor commitments important enough to require continuous security oversight?”
For most biotech firms under $100M, the honest answer is yes.
Internal IT Cannot Be the Whole Security Model
There is a common belief that a strong internal IT team can handle this with the right tools.
Sometimes they can handle pieces of it. They can manage systems. They can support users. They can improve controls. They can coordinate vendors. They can respond during business hours. They can build institutional knowledge that no outside provider will fully replace.
But that does not mean they can function as a 24/7 SOC.
Security operations require different muscle.
It requires threat detection experience, alert triage discipline, escalation procedures, response playbooks, tuning, reporting, investigation skills, and constant availability. It also requires judgment built from seeing patterns across many environments, not just one company.
This is where internal teams often get stretched beyond reason.
They are expected to support the business, secure the environment, respond to incidents, manage vendors, prepare for audits, assist with compliance, and still monitor alerts around the clock. That is not a strategy. That is wishful thinking disguised as resourcefulness.
A company does not reduce risk by assigning security responsibility to people who do not have the time to execute it properly.
It simply creates a model where leadership believes someone is watching, even when no one truly is.
Managed Security Services Are Not a Shortcut
Some biotech leaders hesitate because they think using an MSSP means outsourcing responsibility.
That is the wrong way to look at it.
Managed security services should not replace security ownership. They should strengthen it.
The right MSSP gives biotech companies access to security experience, continuous monitoring, guaranteed response times, after-hours coverage, escalation structure, and operational consistency that would be expensive and difficult to build internally.
This is not about handing off accountability. It is about building a security operating model that matches the risk profile of the business.
A mature managed security model gives internal IT and security leaders more control, not less. It creates visibility into alerts, response activity, incident trends, endpoint behavior, identity risk, vulnerabilities, and recurring exposure. It helps leadership understand whether the security program is improving or simply reacting.
For biotech companies, that matters.
A security partner should help answer practical executive questions:
Are critical alerts being reviewed after hours?
Who responds when an endpoint shows suspicious behavior?
What is the escalation path if a privileged account is compromised?
How quickly are high-severity alerts investigated?
Can we show evidence of monitoring and response activity?
Do we have coverage during holidays, weekends, and staff turnover?
Can our current model support growth, fundraising, partnerships, and compliance expectations?
Those are not vendor questions. Those are operating model questions.
What Biotech Leaders Should Look For
Not every MSSP is a fit for biotech. A generic provider that only forwards alerts will not solve the problem.
Directors of IT, security leaders, and CISOs should evaluate managed security services based on operational substance, not marketing language.
Start with response times. Ask what happens when a critical alert fires at 1:00 a.m. Ask who reviews it, how fast it is triaged, how escalation works, and what evidence is documented.
Then look at experience. Has the provider worked with regulated, research-driven, or IP-sensitive environments? Do they understand the business consequence of research disruption? Can they support environments with cloud platforms, remote teams, lab systems, identity complexity, and third-party collaboration?
Ask about tuning. A SOC that generates noise without context will overwhelm your team. The provider should help reduce false positives, prioritize risk, and mature detection over time.
Ask about reporting. Leadership needs more than technical logs. They need clear insight into incidents, trends, response activity, open risks, and operational exposure.
Ask about integration with your internal team. The goal is not to create a black box. The goal is to create a security extension that helps your team respond faster and make better decisions.
The Real Question
Biotech companies under $100M are often in the most dangerous stage of security maturity.
They have valuable intellectual property, growing operational complexity, remote collaboration, cloud dependency, regulatory pressure, and investor scrutiny. But they may not yet have a fully staffed security operation.
That gap is where attackers operate.
The cost of not having 24/7 SOC coverage is not just financial. It is strategic. It is the cost of delayed awareness. It is the cost of discovering too late that your tools were alerting, but your operating model was not responding.
A biotech company does not need to build everything internally to be serious about security.
But it does need a model that watches when the business is not watching.
If your current security strategy depends on an overloaded internal team noticing the right alert at the right time, the problem is not your team.
The problem is the model.
And the real question for leadership is simple: can that model support the company you are trying to become?
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
Biotech Podcast
On this podcast, we discuss data recovery. This episode explores the significant challenges biotech firms face in developing effective data recovery strategies. Topics include the importance of regular testing, rapid restoration capabilities, and the risks of inadequate planning. It highlights how speed and efficiency are crucial to uninterrupted operations, regulatory compliance, and maintaining trust in a data-driven industry. Tune in to the discussion.
Biotech YouTube
Subscribe to our YouTube channel. On a recent episode,” The Delay That Destroys Biotech”, Most biotech breaches aren’t discovered for months. And by the time they are, the damage is already done. In this episode, we break down what really happens during that silent window and why detection time, not prevention, defines your risk. If you can’t see it early, you can’t control it.
